Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
February 12, 2024
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
January 18, 2024
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
December 27, 2023
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
November 13, 2023
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 3, 2023
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
October 19, 2023
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
October 17, 2023
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
October 17, 2023
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 16, 2023

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe